It is made available under a CC-BY-ND 4.0 International license .

**Title:** Antithrombotic Therapy After Transcatheter Aortic Valve Implantation in Patients with Long-Term Indication for Anticoagulation: Systematic Review and Meta-Analysis

Authors: Gonçalo Costa<sup>1</sup>, MD, MSc; José Pedro Sousa<sup>1</sup>, MD, MSc; Lino Gonçalves<sup>1,2,3</sup>, MD, PhD; Rogério Teixeira<sup>1,2,3</sup>, MD, PhD

<sup>1</sup> Serviço de Cardiologia, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal

<sup>2</sup> Faculdade de Medicina da Universidade de Coimbra, Coimbra, Portugal

<sup>3</sup>Coimbra Institute for Clinical and Biomedical Research (iCBR), Coimbra, Portugal

Running title: Anticoagulation and transcatheter aortic valve implantation

### **Corresponding author:**

Name: Gonçalo Nuno Ferraz Costa

Address: Cardiology Department, Hospital Geral – CHUC, Quinta dos Vales, S. Martinho do Bispo, 3041-801 Coimbra, Portugal

E-mail address: gnfcosta.93@gmail.com

#### Funding

The authors have no conflicts of interest to declare.

## Total word count: 2294 words

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

It is made available under a CC-BY-ND 4.0 International license .

# Abstract

**Objective**: The aim of this study was to compare antithrombotic regimens following transcatheter aortic valve implantation (TAVI) in patients requiring long-term oral anticoagulation (OAC).

**Methods:** We systematically searched PubMed, Embase, and Cochrane databases for interventional and observational studies comparing OAC to OAC plus single antiplatelet therapy (SAPT).

**Results**: Five studies were included (four registry-based and one randomized controlled trial), comprising a total of 1318 patients. Our meta-analysis revealed lower rates of severe bleeding (pooled odds ratio [OR] 0.46 [0.31, 0.69], P<0.01, I<sup>2</sup>=0%) and major bleeding (pooled OR 0.46 [0.27,0.79], P<0.01, I<sup>2</sup>=0%) for the OAC group than for the OAC-plus-SAPT group. There was a nonsignificant trend towards reduced life-threatening bleeding events in the OAC group (pooled OR 0.54 [0.27,1.08], P=0.08, I<sup>2</sup>=11%). There was no difference between groups in the risks of stroke (pooled OR 1.02 [0.58,1.80], P=0.58, I<sup>2</sup>= 0%) or all-cause mortality (pooled OR 1.04 [0.75,1.42], P=0.83, I<sup>2</sup>= 0%) after TAVI.

**Conclusions**: Our pooled analysis suggests that for patients with an indication for longterm OAC after TAVI, double anti-thrombotic therapy, compared to OAC alone, increased the risk of bleeding without reducing cerebrovascular events and all-cause mortality.

Keywords: Atrial Fibrillation; Aortic Stenosis; TAVI; Anticoagulant therapy

# **Key questions:**

# • What is already known about this subject?

Transcatheter Aortic Valve Implantation (TAVI) is a landmark techinique in interventional cardiology with growing clinical experience and continuous refinement of procedural techniques and devices. Nevertheless, the post-TAVI antithrombotic regimen guidelines are largely based on expert opinions and followed variably across the globe.

# • What does this study add?

Our pooled analysis suggests that for patients with an indication for long-term anticoagulation after TAVI, double anti-thrombotic therapy, compared to OAC alone, increased the risk of bleeding without reducing cerebrovascular events and all-cause mortality.

# • How might this impact on clinical practice?

Our finding may prove insightful for future recommendations regarding the conundrum of the best antithrombotic strategy, particularly for patients with AF.

It is made available under a CC-BY-ND 4.0 International license .

#### **Abbreviation index**

- AF Atrial Fibrillation
- AS Aortic Stenosis
- CAD Coronary Artery Disease
- HTN Hypertension
- MI Myocardial Infarction
- NR Non-Reported
- OAC Oral Anticoagulation
- PAD Peripheral Artery Disease
- PRISMA Preferred Reporting Items for Systematic Reviews and Meta-Analyses
- PCI Percutaneous Coronary Intervention
- RCT Randomized Controlled Trial
- SAPT Single Antiplatelet Therapy
- TAVI Transcatheter Aortic-Valve Implantation
- VARC-2 Valve Academic Research Consortium-2
- VKA Vitamin K Antagonist

# INTRODUCTION

Transcatheter aortic valve implantation (TAVI) is used in high-risk patients with symptomatic severe aortic stenosis (AS)(1). The procedure is complicated by major and life-threatening bleeding in 3% to 13% of patients, and the incidental rate of stroke after TAVI varies from 1% to 12%(2,3). Atrial fibrillation (AF) is the most common sustained arrhythmia in the general population. Its prevalence increases with age, affecting more than 10% of people aged  $\geq$  80 years, and, overall, the prevalence and incidence of AF are growing worldwide(4,5). AF is an indication for long-term oral anticoagulation (OAC) with a vitamin K antagonist (VKA) or a direct-acting oral anticoagulant (DOAC)(4,5). AF and AS share multiple common risk factors, including age and hypertension, and AS itself is associated with a higher rate of AF because of pressure overload imposed on the left atrium(6). Optimal peri-TAVI management of

#### It is made available under a CC-BY-ND 4.0 International license .

antithrombotic therapy represents a relevant issue for patients with AF. Current practice recommendations on antithrombotic treatment for patients requiring OAC after TAVI suggest the use of VKA alone(7) or in combination with aspirin or clopidogrel(8). The rationale for the additional therapy is to reduce the risk of thromboembolic complications, but, in patients without a long-term indication for anticoagulation, two randomized trials have not shown a benefit of clopidogrel plus aspirin therapy in terms of reducing ischemic and vascular events following TAVI(9,10). Moreover, a trend towards an increased risk of bleeding was noted for patients on dual antiplatelet therapy(10). Additionally, the recent POPular-TAVI trial cohort B showed that OAC alone was associated with reduced bleeding compared to OAC with clopidogrel in post-TAVI patients requiring long-term OAC(11).

The purpose of this study was to perform a systematic review and meta-analysis of antithrombotic regimens in post-TAVI patients with an indication for OAC. We compared OAC (VKA or DOAC) to OAC combined with single antiplatelet therapy (SAPT), either aspirin or clopidogrel, as antithrombotic treatment following TAVI. Endpoints included bleeding events, ischemic events, and all-cause mortality.

#### **METHODS**

#### Protocol

This study was designed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (**Supplementary Table** 1).

# **Literature Search**

We systematically searched PubMed, Embase, and the Cochrane Controlled Register of Trials (CENTRAL) in April 2020 for interventional and observational studies comparing OAC and OAC plus SAPT in patients undergoing TAVI who had an indication for anticoagulation. The search was limited by language (English, French, Portuguese, or Spanish) and type of subjects (human). No publication date limits were imposed. **Supplementary Figure 1** outlines the search strategy. Additional data were collected from randomized controlled trial (RCT) protocols. Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research

# **Eligibility Criteria**

The following criteria defined study eligibility: 1) interventional or observational studies comparing OAC with OAC plus SAPT in patients undergoing TAVI; 2) participants with symptomatic severe AS; 3) patients with an indication for long-term OAC; and 4) information on bleeding and ischemic complications during the follow-up period. We excluded series with fewer than 20 patients or without full-text article publications.

### **Primary and Secondary Outcomes**

The primary endpoints were severe bleeding, major bleeding, life-threatening bleeding, and intracranial bleeding. Severe bleeding included major and life-threatening events, which were defined according to the Valve Academic Research Consortium-2 (VARC-2) (12). Major bleeding is overt bleeding associated with a decrease in hemoglobin level of  $\geq 3.0$  g/dL or requiring transfusion of two or three units of whole blood/red blood cells (RBC), bleeding causing hospitalization or permanent injury, or bleeding requiring surgery and bleeding that does not meet criteria for life-threatening

It is made available under a CC-BY-ND 4.0 International license .

bleeding. Life-threatening bleeding is fatal bleeding or bleeding in a critical organ, such as intracranial, intraspinal, intraocular, or pericardial bleeding necessitating pericardiocentesis; intramuscular bleeding with compartment syndrome; bleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery; or bleeding associated with a decrease in hemoglobin  $\geq 5$  g/dL or whole blood or packed RBC transfusion  $\geq 4$  units. VARC-2 definitions were used in all the included studies.

Secondary endpoints were all-cause mortality, myocardial infarction (MI), minor bleeding, and all-bleeding events. Stroke included ischemic and hemorrhagic stroke. All-bleeding included severe bleeding and minor bleeding events.

#### **Data Collection and Management**

Two authors (GC, RT) systematically screened the titles and abstracts of publications retrieved to select studies that met the inclusion criteria. Next, they independently assessed the full texts of the studies for eligibility. Data was extracted concerning the study population, main demographics and baseline characteristics, interventions, and outcomes of interest. We analyzed studies with multiple sequenced publications and ensured no duplication of results and collection of the most recent data.

# **Risk of Bias Assessment**

The same two authors (GC, RT) independently assessed the risk of bias of the included articles, following the Cochrane Collaboration's "Risk of bias" tool for RCTs and the Newcastle-Ottawa Scale for observational studies. RCTs were assessed as "low", "high", or "unclear" risk for the following biases: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. The quality

It is made available under a CC-BY-ND 4.0 International license .

assessment for each study is presented in the "Risk of Bias Summary" (**Table 1**) and the Newcastle-Ottawa Scale Summary (**Table 2**).

## **Statistical Analysis**

We pooled dichotomous non-adjusted data using odds ratios (OR) to describe effect sizes using the Mantel-Haenszel procedure in a random effects model. Study heterogeneity was evaluated by funnel plots. The mean effect was considered significant if its 95% confidence interval (CI) did not include zero. Heterogeneity was assessed using the I<sup>2</sup> statistic and assumed to be relevant if it exceeded 50%.

### RESULTS

# **Search Results**

Our search identified 14,726 articles, including one RCT (POPular-TAVI Cohort B). After removal of duplicates, we excluded 14,241 publications according to title and abstract evaluation, study type, and study population. Finally, five publications met all inclusion criteria, providing a total of 1318 patients for the meta-analysis (**Figure 1**). Study characteristics are shown in **Table 3**.

### **Primary Outcomes**

Our meta-analysis revealed lower rates of severe bleeding (pooled OR 0.48 [0.34, 0.69], P<0.01, I<sup>2</sup>=0%) (**Figure 2**) and major bleeding (pooled OR 0.55 [0.36, 0.86], P<0.01, I<sup>2</sup>=0%) in the OAC group than in the OAC-plus-SAPT group. There was a nonsignificant trend towards reduced life-threatening bleeding events favoring the OAC group (pooled OR 0.54 [0.27, 1.08], P=0.08, I<sup>2</sup>=11%), but similar rates of intracranial bleeding were observed in the groups (pooled OR 1.57 [0.39, 6.24], P=0.52,

It is made available under a CC-BY-ND 4.0 International license .

I<sup>2</sup>=12%). No significant heterogeneity or selection/publication bias was identified (**Supplementary Figures 2**).

### **Secondary Endpoints**

There was no difference between the OAC and OAC-plus-SAPT groups in terms of stroke prevention after TAVI (pooled OR 0.98 [0.57, 1.70], P=0.58, I<sup>2</sup>=0%) (**Figure 3**). There were also similar rates of all-cause mortality (pooled OR 1.04 [0.75, 1.42], P=0.83, I<sup>2</sup>=0%) (**Figure 4**) and MI (pooled OR 0.36 [0.04, 3.07], P=0.35, I<sup>2</sup>=16%). Additionally, the composite endpoint of all-bleeding events was lower in the OAC group than in the OAC-plus-SAPT group (pooled OR 0.52 [0.38, 0.72], P<0.01, I<sup>2</sup>=0%) (**Figure 1**). Minor bleeding events were similar between groups (pooled OR 0.68 [0.42, 1.11], P=0.13, I<sup>2</sup>=0%). No selection or publication bias was identified by funnel plots (**Supplementary Figures 2-4**).

## DISCUSSION

According to our systematic review and meta-analysis, for patients requiring long-term OAC after TAVI, the use of double anti-thrombotic therapy, compared to the use of OAC alone, significantly increased the risk of bleeding, including major events. No significant differences were noted regarding ischemic events or all-cause mortality.

Antiplatelet therapy is combined with anticoagulation to prevent thromboembolic complications before valve endothelialization is completed, but this is a controversial practice in interventional cardiology. American and European guidelines on post-TAVI antithrombotic regimens consider the flow conditions of a bioprosthetic valve similar to a coronary stent(4,5,7,8,13). Many patients with AF have concomitant coronary artery disease (CAD) and undergo percutaneous coronary intervention (PCI) with stenting. These patients often receive aspirin therapy in addition to OAC. This It is made available under a CC-BY-ND 4.0 International license .

combination reduces ischemic and thrombotic events but increases the risk of major bleeding by 2- to 3-fold (14,15).

The risk of bleeding with combined OAC plus antiplatelet therapy is related to the degree of anticoagulation, patient characteristics, and comorbidities. The patients in our analysis had a high-risk profile, so our pooled results do not apply to younger or intermediate- to low-risk patients(16,17).

## **Post-TAVI Stroke Rate**

A recent analysis of the Transcatheter Valve Therapy Registry reported a stable 30-day stroke risk after TAVI in the first five years after the procedure's approval by the United States Food and Drug Administration(18). Improvements in TAVI technology and operator experience positively impacted major post-TAVI complications such as bleeding, vascular injury, and mortality but did not translate into a reduced stroke rate(19).

A potential strategy to prevent embolic events during TAVI is the use of embolic protection devices. A recent meta-analysis suggested that the use of such devices appears to be associated with a nonsignificant trend towards reduced death or stroke(20). Future evidence related to this issue could lead to a significant decrease in stroke risk after TAVI.

A left atrial appendage thrombus is a potential source of post-TAVI stroke for AF patients(21). The ongoing WATCH-TAVR trial is a prospective, multicenter, RCT (NCT03173534) that is evaluating the safety and effectiveness of left atrial appendage occlusion for the prevention of stroke and bleeding hazards in patients with AF undergoing TAVI.

It is made available under a CC-BY-ND 4.0 International license .

In most TAVI studies, baseline populations include patients with AS who were rendered unsuitable for surgical aortic replacement (SAVR), meaning they are elderly patients with high operative risk(22). This subset of patients commonly has several comorbidities that impact embolic and bleeding events(23). Two recent trials assessing the value of TAVI in low-risk patients demonstrated non-inferiority of the technique when compared with SAVR for major outcomes, which will likely expand TAVI indications(24,25). One of these trials reported no mortality or stroke events at 30 days, demonstrating the safety of the procedure(24). Nevertheless, leaflet thrombosis, a potential risk factor for stroke and transient ischemic attacks, was reported in a minority of patients, although there was no association with clinical events. Therefore, long-term follow-up of these patients will be important for understanding the impact of subclinical leaflet thrombosis and determining the best antithrombotic management for this subset of patients(26).

An important confounding variable in our study is PCI prior to TAVI. Concomitant antiplatelet therapy is recommended in patients with unstable CAD or following stenting, with triple antithrombotic therapy as a reasonable approach in this specific setting. The POPular-TAVI trial excluded patients with drug-eluting stent implantation within 3 months and bare-metal stent implantation within 1 month prior to TAVI(11). It did not show a significant difference in the prevalence of coronary disease or previous MI between the two treatment arms. However, the same findings were not true in the rest of the included studies.

### Future: VKA versus DOACs after TAVI?

DOACs were developed to overcome the limitations of VKA: they have demonstrated a consistently favorable efficacy/safety profile for the prevention of thromboembolic complications of AF and are widely used in clinical practice(27,28). In

10

It is made available under a CC-BY-ND 4.0 International license .

a meta-analysis of four AF trials comparing DOACs with VKA, the rates of intracranial hemorrhage were nearly halved with DOACs and ischemic stroke and mortality were also significantly reduced(29). These conclusions were similar for patients with non-valvular AF and concomitant aspirin therapy(30).

The broad use of DOACs in clinical practice is reflected in the original POPular-TAVI trial, in which DOAC use was an exclusion criteria, but it was not fully eliminated from the ultimate patient sample(31). Furthermore, a prespecified subgroup analysis of this trial showed a possible benefit of DOACs over VKA regarding bleeding or ischemic outcomes(11). Nevertheless, most of the available data on DOACs after TAVI are registry-based; they show an improved safety profile with no difference in ischemic outcomes when compared with VKA(32). Additionally, in the RESOLVE and SAVORY registries, there were no significant differences in reduced leaflet motion between DOAC and warfarin; both appeared better than no anticoagulation(33). A substudy of the ENGAGE AF-TIMI 48 trial, comprising 91 patients with previous transcatheter or surgical bioprosthetic valve implantation and AF demonstrated a significant reduction of major bleeding with low-dose (30 mg) edoxaban compared with warfarin(33). Thus, DOAC-based antithrombotic regimens seem a valid treatment option in patients undergoing TAVI who require long-term OAC. The ongoing ENVISAGE-TAVI AF (NCT02943785) is expected to reveal more insight into this issue.

### Limitations

The studies included in our meta-analysis primarily compared VKA-based treatments, which is a major limitation of this study. Another important limitation of our meta-analysis is the paucity of RCTs on this issue. In fact, most studies included were observational, which increases the risk of bias and limits the strength of our results.

Minor bleeding was defined differently in the included studies and between centers in the POPular-TAVI trial. Substantial heterogeneity exists between studies in terms of design and type and duration of antiplatelet/antithrombotic therapy used. Nevertheless, the heterogeneity did not affect our analysis, and all  $I^2$  values were < 50%. Additionally, most of the studies did not report the incidence of MI and some did not differentiate type of stroke.

Another limitation of our analysis is that no study distinguished forms of intracranial bleeding other than hemorrhagic stroke, which could underrepresent the real incidence of this outcome. Furthermore, antiplatelet therapy duration and specific antiplatelet drug used in the antithrombotic regimen were not reported or differed among studies. Consequently, these comparisons should be interpreted with caution.

# CONCLUSION

Our pooled analysis suggests that for patients with an indication for long-term OAC after TAVI, the use of double anti-thrombotic therapy (OAC with SAPT), compared to the use of OAC alone, increased the risk of bleeding without reducing all-cause mortality and cerebrovascular events.

# FUNDING

The authors have no conflictics of interest to declare

# REFERENCES

 Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter Aortic-Valve Implantation for Aortic Stenosis in Patients Who Cannot Undergo Surgery. N Engl J Med [Internet]. 2010 Oct 21 [cited 2020 May 22];363(17):1597–607. Available from:

It is made available under a CC-BY-ND 4.0 International license .

http://www.nejm.org/doi/abs/10.1056/NEJMoa1008232

- Chieffo A, Petronio AS, Mehilli J, Chandrasekhar J, Sartori S, Lefèvre T, et al. 1-Year Clinical Outcomes in Women After Transcatheter Aortic Valve Replacement: Results From the First WIN-TAVI Registry. JACC Cardiovasc Interv. 2018 Jan 8;11(1):1–12.
- Manoharan G, Van Mieghem NM, Windecker S, Bosmans J, Bleiziffer S, Modine T, et al. 1-Year Outcomes With the Evolut R Self-Expanding Transcatheter Aortic Valve: From the International FORWARD Study. JACC Cardiovasc Interv. 2018 Nov 26;11(22):2326–34.
- Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J [Internet]. 2016 Aug 27;37(38):2893– 962. Available from: https://doi.org/10.1093/eurheartj/ehw210
- 5. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation [Internet]. 2019 Jul 9 [cited 2020 May 22];140(2):e125–51. Available from: https://www.ahajournals.org/doi/10.1161/CIR.000000000000665
- Tarantini G, Mojoli M, Urena M, Vahanian A. Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome. Eur Heart J [Internet]. 2016 Oct 12;38(17):1285–93.

Available from: https://doi.org/10.1093/eurheartj/ehw456

- Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J [Internet]. 2017 Aug 26;38(36):2739–91. Available from: https://doi.org/10.1093/eurheartj/ehx391
- Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, et al. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Vol. 135, Circulation. Lippincott Williams and Wilkins; 2017. p. e1159–95.
- 9. Stabile E, Pucciarelli A, Cota L, Sorropago G, Tesorio T, Salemme L, et al. SAT-TAVI (single antiplatelet therapy for TAVI) study: A pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. Int J Cardiol. 2014 Jul 1;174(3):624–7.
- Rodés-Cabau J, Masson JB, Welsh RC, Garcia del Blanco B, Pelletier M, Webb JG, et al. Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial. JACC Cardiovasc Interv. 2017 Jul 10;10(13):1357–65.
- Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, et al. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. N Engl J Med. 2020 Mar 29;

- Kappetein AP, Head SJ, Généreux P, Piazza N, Van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: The Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg. 2013 Jan 1;145(1):6–23.
- Holmes DR, MacK MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, et al.
  2012 ACCF/AATS/SCAI/STS expert consensus document on transcatheter aortic valve replacement. J Am Coll Cardiol. 2012 Mar 27;59(13):1200–54.
- Chen CF, Chen B, Zhu J, Xu YZ. Antithrombotic therapy after percutaneous coronary intervention in patients requiring oral anticoagulant treatment: A metaanalysis. Vol. 40, Herz. Urban und Vogel GmbH; 2015. p. 1070–83.
- 15. Andrade JG, Deyell MW, Khoo C, Lee M, Humphries K, Cairns JA. Risk of Bleeding on Triple Antithrombotic Therapy After Percutaneous Coronary Intervention/Stenting: A Systematic Review and Meta-analysis. Vol. 29, Canadian Journal of Cardiology. Can J Cardiol; 2013. p. 204–12.
- Popma JJ, Michael Deeb G, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med. 2019 May 2;380(18):1706–15.
- Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in lowrisk patients. N Engl J Med. 2019 May 2;380(18):1695–705.
- Huded CP, Tuzcu EM, Krishnaswamy A, Mick SL, Kleiman NS, Svensson LG, et al. Association between Transcatheter Aortic Valve Replacement and Early Postprocedural Stroke. JAMA - J Am Med Assoc. 2019 Jun 18;321(23):2306–15.

- Carroll JD, Vemulapalli S, Dai D, Matsouaka R, Blackstone E, Edwards F, et al. Procedural Experience for Transcatheter Aortic Valve Replacement and Relation to Outcomes: The STS/ACC TVT Registry. J Am Coll Cardiol. 2017 Jul 4;70(1):29–41.
- Giustino G, Sorrentino S, Mehran R, Faggioni M, Dangas G. Cerebral Embolic Protection During TAVR: A Clinical Event Meta-Analysis. Vol. 69, Journal of the American College of Cardiology. Elsevier USA; 2017. p. 465–6.
- Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Vol. 61, Annals of Thoracic Surgery. Elsevier USA; 1996. p. 755–9.
- Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, Tornos P, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005 Dec;26(24):2714–20.
- Kappetein AP, van Geldorp M, Takkenberg JJM, Bogers AJJC. Optimum management of elderly patients with calcified aortic stenosis. Expert Rev Cardiovasc Ther. 2008 Apr;6(4):491–501.
- Waksman R, Corso PJ, Torguson R, Gordon P, Ehsan A, Wilson SR, et al. TAVR in Low-Risk Patients: 1-Year Results From the LRT Trial. JACC Cardiovasc Interv. 2019 May 27;12(10):901–7.
- Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O'Hair D, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. N Engl J Med [Internet]. 2019 May 2 [cited 2020 May 22];380(18):1706–15. Available from:

http://www.nejm.org/doi/10.1056/NEJMoa1816885

- 26. Czerwińska-Jelonkiewicz K, Zembala M, Dąbrowski M, Witkowski A, Ochała A, Kochman J, et al. Can TAVI patients receive aspirin monotherapy as patients after surgical aortic bioprosthesis implantation? Data from the Polish Registry POL-TAVI. Int J Cardiol. 2017 Jan 15;227:305–11.
- Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981–92.
- Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–91.
- 29. Katsanos AH, Schellinger PD, Köhrmann M, Filippatou A, Gurol ME, Caso V, et al. Fatal oral anticoagulant-related intracranial hemorrhage: a systematic review and meta-analysis. Eur J Neurol. 2018 Oct 1;25(10):1299–302.
- 30. Bennaghmouch N, de Veer AJWM, Bode K, Mahmoodi BK, Dewilde WJM, Lip GYH, et al. Efficacy and Safety of the Use of Non–Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy. Circulation [Internet]. 2018 Mar 13 [cited 2020 May 24];137(11):1117–29. Available from: https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.028513
- 31. Nijenhuis VJ, Bennaghmouch N, Hassell M, Baan J, Van Kuijk JP, Agostoni P, et al. Rationale and design of POPular-TAVI: AntiPlatelet therapy for Patients undergoing Transcatheter Aortic Valve Implantation. Am Heart J. 2016 Mar 1;173:77–85.
- 32. Seeger J, Gonska B, Rodewald C, Rottbauer W, Wöhrle J. Apixaban in Patients

With Atrial Fibrillation After Transfemoral Aortic Valve Replacement. JACC Cardiovasc Interv. 2017 Jan 9;10(1):66–74.

33. Chakravarty T, Søndergaard L, Friedman J, De Backer O, Berman D, Kofoed KF, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017 Jun 17;389(10087):2383–92.

It is made available under a CC-BY-ND 4.0 International license .

# Tables



# Table 1. Risk of Bias Summary

# Table 2. Newcastle-Ottawa Scale Summary

	Selection	Comparability	Outcome
D'Ascenzo 2017	****	*	**
Geis 2017	***	*	**
Abdul-Jawad	****	*	**
Altisent 2016			
Czerwińska-	****	_	**
Jelonkiewicz 2016			

# Table 3. Main Characteristics of Included Studies

Study	Regimen	Number of patients	Duration of follow-up, mnths	Post-TAVI Antithrombotic protocol	Type of valve	
Nijenhuis et al. 2020	OAC	164	12	OAC: VKA or DOAC	According to local protocol	
	OAC+SAPT	162		SAPT: Clopidogrel 3 months		
D'Ascenzo et al.2017	OAC	105	6	OAC: VKA	Edwards SAPIEN and	
	OAC+SAPT	105		SAPT: Aspirin 6 months	SAPIEN XT prostheses	
Geis et al. 2017	Geis et al. 2017 OAC 77 6		OAC: VKA	Edwards SAPIEN 3, SAPIEN XT, Direct Flow		
	OAC+SAPT	41	-	SAPT: Aspirin or Clopidogrel	Medical and CoreValve prostheses	
Abdul-Jawad Altisent et al. 2016	OAC	101	13	OAC: VKA	Edwards SAPIEN, SAPIEN	
riodal suvad ridisent et al. 2010	OAC+SAPT	463	-	SAPT: Aspirin or Clopidogrel	3, SAPIEN XT and CoreValve prosthesis	
Czerwińska-Jelonkiewicz et al.	OAC	38	12	OAC: VKA		
2016	OAC+SAPT	128	- 12	SAPT: Aspirin or clopidogrel	prosthesis	
OAC - Oral Anticoagulation; SAPT -	– Single Antiplate	elet Therapy; VKA – V	Vitamin K Antagonis			

It is made available under a CC-BY-ND 4.0 International license .

Study	Regimen	Age (years)	Female gender (%)	Atrial Fibrillation (%)	Diabetes (%)	HTN (%)	CAD (%)	PAD (%)	Previous MI (%)	Previous stroke (%)
Nijenhuis et al. 2020	OAC	80.9±6.2	44	95.5	27.4	73.2	41.4	19.1	8.9	9.3
	OAC+SAPT	81.0±5.5	47	94.2	29.5	67.3	44.2	17.9	12.8	9.6
D'Ascenzo et al.2017	OAC	81±5	58	60	24	82	24	38	13	NR
	OAC+SAPT	82±6	61	63	33	81	24	41	15	NR
Geis et al. 2017	OAC	83.6±4.7	60	100	37.7	93.5	50.6	NR	NR	11.7
	OAC+SAPT	82.7±4.8	59	100	36.6	100	63.4	NR	NR	17.1
Abdul Jawad Alticent et al. 2016	OAC	81.0±7	49	100	35.6	NR	24	NR	NR	19.8
Abdul-Jawad Anisent et al. 2010	OAC+SAPT	82.0±7	61	100	32.3	NR	51.5	NR	NR	19.6
Czerwińska-Jelonkiewicz et al. 2016	OAC OAC+SAPT	79.31 ± 7.35	55.3	NR	35.6	NR	31.6	NR	26.4	6.7

# Table 4. Clinical features in included studies

CAD – Coronary Artery Disease; HTN – Hypertension; MI – Myocardial Infarction; OAC – Oral Anticoagulation; PAD – Peripheral Artery Disease; SAPT – Single Antiplatelet Therapy; VKA – Vitamin K Antagonist

It is made available under a CC-BY-ND 4.0 International license .

It is made available under a CC-BY-ND 4.0 International license .

# **Figure Titles and Legends**



Figure 1. Flow diagram of literature search.

#### It is made available under a CC-BY-ND 4.0 International license .

	OAO		OAC+S	APT		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Random, 95% Cl	M-H, Random, 95% Cl
1.1.1 Severe Bleeding							
Abdul-Jawad Altisent et al 2016	15	101	118	463	36.8%	0.51 [0.28, 0.92]	
D'ascenzo et al 2017	2 19	105	20	105	5.7% 29.5%	0.22 [0.05, 0.96]	· · · ·
Geis et al 2017	0	77	3	41	1.4%	0.07 [0.00, 1.41]	•
Nijenhuis et al 2020	14	164	26	162	26.6%	0.49 [0.24, 0.97]	
Subtotal (95% CI)	<b>CO</b>	485	202	899	100.0%	0.48 [0.34, 0.69]	-
Heterogeneity: $Tau^2 = 0.00$ ; $Chi^2 = 3$	05 df= 4 (	P = 0.5	202 5): IP = 09	6			
Test for overall effect: Z = 3.99 (P < 0	0.0001)	. 0.0	•/,• •/	•			
1.1.2 Major Bleeding							
Abdul-Jawad Altisent et al 2016	10	101	94	463	40.9%	0.43 [0.22, 0.86]	<b>_</b>
D'ascenzo et al 2017	14	105	17	105	33.3%	0.80 [0.37, 1.71]	
Geis et al 2017	0	77	2	41	2.1%	0.10 [0.00, 2.18]	4
Nijenhuis et al 2020 Subtotal (95% CI)	8	164	13	162	23.7%	0.59 [0.24, 1.46]	
Total events	32	447	126		100.0%	0.55 [0.50, 0.00]	
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 2.	.58, df = 3 (	P = 0.4	6); I <sup>2</sup> = 09	6			
Test for overall effect: Z = 2.63 (P = 0	).009)						
1.1.3 Minor bleeding							
Abdul-Jawad Altisent et al 2016	2	101	17	463	10.9%	0.53 [0.12, 2.33]	
D'ascenzo et al 2017	8	105	9	105	24.1%	0.88 [0.33, 2.38]	
Geis et al 2017	1	77	1	41	3.0%	0.53 [0.03, 8.64]	· · · · · · · · · · · · · · · · · · ·
Nijenhuis et al 2020 Subtotal (95% CI)	20	164 447	28	162 771	61.9% 100.0%	0.66 [0.36, 1.24]	
Total events	31		55		1001070	0.00 [0.42, 1.12]	
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0.	40, df = 3 (	P = 0.9	4); I <sup>2</sup> = 09	6			
Test for overall effect: Z = 1.50 (P = 0	).13)						
1.1.4 Life-threatning bleeding							
Abdul-Jawad Altisent et al 2016	3	101	9	463	23.6%	1.54 [0.41, 5.81]	
D'ascenzo et al 2017	5	105	12	105	33.5%	0.39 [0.13, 1.14]	
Geis et al 2017 Nijephuje et al 2020	0	164	12	44	4.4%	0.19 [0.01, 4.69]	
Subtotal (95% CI)	0	447	15	774	100.0%	0.54 [0.27, 1.08]	
Total events	14		35				
Heterogeneity: Tau <sup>2</sup> = 0.06; Chi <sup>2</sup> = 3.	.39, df = 3 (	P = 0.3	4); I <sup>2</sup> = 11	%			
Test for overall effect: $Z = 1.75$ (P = 0	1.08)						
1.1.5 Intracranial bleeding							
Abdul-Jawad Altisent et al 2016	3	101	6	463	66.1%	2.33 [0.57, 9.48]	
Geis et al 2017 Nijephyje et el 2020	0	164	1	41	16.9%	0.17 [0.01, 4.37]	
Subtotal (95% CI)		342	U	666	100.0%	1.57 [0.39, 6.24]	
Total events	4		7				
Heterogeneity: Tau <sup>2</sup> = 0.24; Chi <sup>2</sup> = 2.	.28, df = 2 (	P = 0.3	2); I <sup>2</sup> = 12	%			
Test for overall effect: Z = 0.64 (P = 0	1.52)						
1.1.6 All-bleeding							
Abdul-Jawad Altisent et al 2016	15	101	120	463	29.1%	0.50 [0.28, 0.90]	
D'ascenzo et al 2017	27	105	38	105	28.6%	0.61 [0.34, 1.10]	
oeisetaizut7 Nijenhuisetai2020	1 34	164	4 54	41	∠.U% 40.2%	0.12 [0.01, 1.13] 0.52 [0.32 -0.86]	
Subtotal (95% CI)	- 54	447		771	100.0%	0.52 [0.38, 0.72]	▲
Total events	77		216				
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.	.94, df = 3 (	P = 0.5	9); I <sup>z</sup> = 09	6			
restion overall effect: Z = 4.01 (P < 0	.0001)						
	0.00.41	- m	0.040 15				Favours OAC Favours OAC plus SAPT
Lest for subgroup differences: Chi*:	= 3.62, df =	5 (P =	U.61), I <sup>#</sup> =	U% 0			

Figure 2. Forest Plot of Bleeding Events Comparing OAC versus OAC plus SAPT.

It is made available under a CC-BY-ND 4.0 International license .







# Figure 4. Forest Plot of All-Cause Mortality Comparing OAC versus OAC plus

### SAPT.



preprint (which was not certified by neer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

Study or Subgroup	Eventsti	s <b>Trotad</b> e a	Evailable u	indetal	CWBIGND	40-Hitecaatibonal ligensec.	M-H, Random, 95% Cl
1.1.1 Severe Bleeding							
Abdul-Jawad Altisent et al 2016	15	101	118	463	36.8%	0.51 [0.28, 0.92]	
CzerwińskaJelonkiewicz et al 2017	2	38	26	128	5.7%	0.22 [0.05, 0.96]	4
D'ascenzo et al 2017	19	105	29	105	29.5%	0.58 [0.30, 1.12]	
Geis et al 2017	0	77	3	41	1.4%	0.07 [0.00, 1.41]	•
Nijenhuis et al 2020	14	164	26	162	26.6%	0.49 [0.24, 0.97]	
Subtotal (95% CI)		485		899	100.0%	0.48 [0.34, 0.69]	◆
Total events	50		202				
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 3. Test for overall effect: Z = 3.99 (P < 0	05, df = 4 (f .0001)	P = 0.55	5); I² = 0%				
1.1.2 Major Bleeding							
Abdul-Jawad Altisent et al 2016	10	101	94	463	40.9%	0.43 [0.22, 0.86]	
D'ascenzo et al 2017	14	105	17	105	33.3%	0.80 [0.37, 1.71]	
Geis et al 2017	0	77	2	41	2.1%	0.10 [0.00, 2.18]	4
Nijenhuis et al 2020	8	164	13	162	23.7%	0.59 [0.24, 1.46]	
Subtotal (95% CI)		447		771	100.0%	0.55 [0.36, 0.86]	-
Total events	32		126				
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 2. Test for overall effect: Z = 2.63 (P = 0	58, df = 3 (f .009)	P = 0.48	6); I² = 0%	5			
1.1.3 Minor bleeding							
Abdul-Jawad Altisent et al 2016	2	101	17	463	10.9%	0.53 [0.12, 2.33]	
D'ascenzo et al 2017	8	105	9	105	24.1%	0.88 [0.33, 2.38]	
Geis et al 2017	1	77	1	41	3.0%	0.53 [0.03, 8.64]	
Nijenhuis et al 2020 Subtotal (95% CI)	20	164 447	28	162 771	61.9% 100.0%	0.66 [0.36, 1.24]	
Total events	31		55				
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 0. Test for overall effect: $Z = 1.50$ (P = 0	40, df = 3 (f .13)	P = 0.94	l); I <sup>z</sup> = 0%	5			
1.1.4 Life-threatning bleeding							
Abdul-Jawad Altisent et al 2016	3	101	9	463	23.6%	1.54 [0.41, 5.81]	
D'ascenzo et al 2017	5	105	12	105	33.5%	0.39 [0.13, 1.14]	
Geis et al 2017	0	77	1	44	4.4%	0.19 [0.01, 4.69]	· · · · · · · · · · · · · · · · · · ·
Nijenhuis et al 2020	6	164	13	162	38.5%	0.44 [0.16, 1.17]	
Subtotal (95% CI)		447		774	100.0%	0.54 [0.27, 1.08]	
Total events	14		35				
Heterogeneity: Tau <sup>2</sup> = 0.06; Chi <sup>2</sup> = 3. Test for overall effect: $Z = 1.75$ (P = 0	39, df = 3 (f 08)	P = 0.34	l); I² = 11	%			
1.1.5 Intracranial bleeding							
Abdul-Jawad Altisent et al 2016	3	101	6	463	66.1%	2.33 [0.57, 9.48]	
Geis et al 2017	0	77	1	41	16.9%	0.17 [0.01, 4.37]	← ■
Nijenhuis et al 2020	1	164	0	162	17.0%	2.98 [0.12, 73.73]	
Subtotal (95% CI)		342		666	100.0%	1.57 [0.39, 6.24]	
Total events	4		7				
Heterogeneity: Tau <sup>2</sup> = 0.24; Chi <sup>2</sup> = 2. Test for overall effect: $Z = 0.64$ (P = 0	28, df = 2 (f .52)	P = 0.32	2); <b>I</b> ² = 12	%			
1.1.6 All-bleeding							
Abdul-Jawad Altisent et al 2016	15	101	120	463	29.1%	0.50 [0.28, 0.90]	
D'ascenzo et al 2017	27	105	38	105	28.6%	0.61 [0.34, 1.10]	
Geis et al 2017	1	77	4	41	2.0%	0.12 [0.01, 1.13]	•
Nijenhuis et al 2020 Subtotal (95% CI)	34	164 447	54	162 771	40.2% 100.0%	0.52 [0.32, 0.86]	-
Total events	77	10000	216				
Heterogeneity: Tau <sup>2</sup> = 0.00; Chi <sup>2</sup> = 1.	94, df = 3 (F	P = 0.59	9); I² = 0%	ò			
Test for overall effect: $Z = 4.01$ (P < 0	.0001)						
Test de la character d'étaire de la character d'étaire	0.00 .40	c (n) - c	0.043 17	~~			Favours OAC Favours OAC plus SAPT

Test for subgroup differences: Chi<sup>2</sup> = 3.62, df = 5 (P = 0.61), l<sup>2</sup> = 0%

-



